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MicroﬂuidicsSequence capture methods for targeted next generation sequencing promise to massively reduce cost of
genomics projects compared to untargeted sequencing. However, evaluated capture methods speciﬁcally
dedicated to biologically relevant genomic regions are rare. Whole exome capture has been shown to be a
powerful tool to discover the genetic origin of disease and provides a reduction in target size and thus
calculative sequencing capacity of N90-fold compared to untargeted whole genome sequencing. For further
cost reduction, a valuable complementing approach is the analysis of smaller, relevant gene subsets but
involving large cohorts of samples. However, effective adjustment of target sizes and sample numbers is
hampered by the limited scalability of enrichment systems. We report a highly scalable and automated
method to capture a 480 Kb exome subset of 115 cancer-related genes using microﬂuidic DNA arrays. The
arrays are adaptable from 125 Kb to 1 Mb target size and/or one to eight samples without barcoding
strategies, representing a further 26 – 270-fold reduction of calculative sequencing capacity compared to
whole exome sequencing. Illumina GAII analysis of a HapMap genome enriched for this exome subset
revealed a completeness of N96%. Uniformity was such that N68% of exons had at least half the median depth
of coverage. An analysis of reference SNPs revealed a sensitivity of up to 93% and a speciﬁcity of 98.2% or
higher.erer).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The enormous capacity of Next Generation Sequencing (NGS)
instruments has dramatically changed the scope and comprehensive-
ness of genomics studies [1–8]. Beside current large scale studies like
the 1000 genomes project that are mainly addressed by a limited
number of genome centers, the possibility of sequencing relevant
subsets of a genome with high sample throughput and at low cost has
become a major interest of numerous researchers.
Several new concepts for sequence enrichment have been
reported recently that have started to provide a means for efﬁcient,
targeted NGS projects. However, these methods still suffer from
various drawbacks like limited scalability in terms of sample numbers,
poor uniformity resulting in partial dropout of target coverage and
time-consuming and complicated workﬂows [9–11]. Three basic
principles of solution phase sequence capture have been reported so
far, with each having its own advantages and drawbacks. Molecular
inversion probes (MIP) or Selector probes have been used for
enrichment of multiple discontinuous target regions with partiallyhigh grade of multiplexing and completeness, i.e. percent of target
covered [12,13]. However, relatively low uniformity of coverage was
also reported and part of the sequencing information was attributed
to artiﬁcal probe sequence introduced during the enrichment work-
ﬂow [12–14].
Solution phase enrichment with very long, biotinylated RNA
probes has been reported recently [15,16]. However, a drawback of
themethodwas amulti-step capture probe library construction with
the potential to introduce bias. Moreover, the length of probes
resulted in overrepresentation of off-target reads for short end
sequencing that could only be overcome by complicated construction
of shotgun libraries or more expensive long read sequencing [15].
Finally, PCR in microdroplets has been demonstrated for sequence
enrichment [17], but ﬂexibility of this approach is limited by the
requirement of individually synthesized primers and suffers from
the fact that primer binding sites have to be designed outside of
the actual target regions to avoid nonsense reads from primers
incorporated into enriched amplicons. This reduces the amount
of relevant informationwithin the sequencers base output andmight
complicate ampliﬁcation of regions surrounded by repetitive
sequence.
The majority of sequence enrichment methods reported so far was
based on solid phase capture using in situ synthesized DNA
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have relatively short and simple workﬂows compared to solution
phase capturing. A reported drawbackwas the need for relatively long
hybridization times compared to solution phase capture. Three array
formats have been used for targeted NGS to date, all allowing for in
situ synthesis of capture probes and thus providing high ﬂexibility of
targeted sequences.
However, for all enrichment approaches, setups dedicated to
selected subsets of biologically meaningful genomic loci have been
rare. Two very recent studies described the enrichment of the whole
human exome with a target size of 26.6 - 34 Mb using microarray
capture with two different formats [25,27]. This approach has proven
to be a powerful discovery tool, i.e. to reveal the genetic origin of
disease by comprehensive exome sequencing of a limited number of
individuals [24]. However, owing to the comprehensiveness of the
method, signiﬁcant capacity of not scalable microarrays had to be
used for enrichment per sample and multiple sequencing instrument
compartments were needed to achieve good coverage depths and
completenesses [25,27].
A valuable complementing approach would be the analysis of a
smaller subset of relevant genes but involving large cohorts of
samples. This would for example allow for an efﬁcient follow-up of
genome wide association studies involving whole genome or whole
exome sequencing or for other focused studies involving gene sets
known to be involved in e.g. cancer development, cardiovascular
diseases or drug response. From an economic point of view, such
projects would greatly beneﬁt from enrichment systems that are
highly scalable to achieve effective further downsizing of targets and
increase of sample numbers. Compared to untargeted sequencing,
whole exome enrichment approaches represent a drastic reduction in
calculative sequencing capacity of 94 – 120-fold. Consequently,
focused analysis of relevant genomic subsets with target sizes in the
range of several hundred Kb to 1 Mb represent a further reduction in
the same order of magnitude.
We report a scalable approach termed HybSelect for selective
capturing of focused exome subsets using compartmentalized,
microﬂuidic biochips. The biochips can be processed with up to
eight samples in parallel without barcoding strategies and are
applicable to target sizes between 125 Kb and 1 Mb. This represents
a reduction of calculative sequencing effort of 26 – 270-fold compared
to current whole exome approaches. We demonstrate selective
capture and sequencing of 115 cancer-related genes with a target
size of 0.48 Mb resulting in a capacity of 2 samples per biochip
without barcoding strategies. Moreover, the method uses a very
simple workﬂow and is highly automated with potential beneﬁts for
cost, reproducibility and contamination risk.
Materials and Methods
Microarray Design and Synthesis
Light-activated in situ oligonucleotide synthesis on Geniom
Biochips was performed as described previously [28]. One Biochip
holds eight individual, microﬂuidic channels each containing an array
of 15.624 individual DNA probe features of which ∼120.000 are
available for custom probes.
Exon sequences of 115 cancer-related genes from the cancer
genome project were downloaded from NCBI and 55.589 50mer
probes were tiled across the exon targets of the full region with an
average probe density of 9 bp targeting sense and antisense strand in
an alternating manner. Each exon was covered by at least 17 probes,
i.e. small exons were extended to ﬁt the tiling scheme. The full region
of interest (ROI) was 9.2 Mb, corresponding to a core target actually
containing exonic sequence of 0.48 Mb. Calculated for the whole
biochip, this corresponds to a total capacity of ∼20 Mb ROI or N1 Mb
target size.DNA sample preparation
The human genomic DNA sample NA18507 was obtained from
Coriell repositories. 5 µg were dissolved in 80 µl of water and
fragmented 2 times for 15 min by sonication at medium intensity
(Bioruptor, Diagenode, Liége, Belgium). An end repair was performed
using T4 DNA polymerase, Klenow Fragment of E. coli DNA
polymerase I and T4 PNK in T4 DNA ligase buffer for 30 min at 20 °C
(all NEB, Ipswich, USA). After puriﬁcation using the MinElute PCR
puriﬁcation protocol (Qiagen, Hilden, Germany), A deoxynucleotides
were added to polished doublestrands using the Klenow fragment (3´-
5´- exo-, Qiagen) in presence of 200 µM dATP in Klenow fragment
reaction buffer for 30 min at 37 °C. After another MinElute PCR
puriﬁcation, Illumina paired end sequencing adaptors were ligated
according to the manufactures protocol. After a Qiaquick PCR
puriﬁcation (Qiagen), ligation mixture was loaded onto a 2% agarose
TBE gel and a library band of 200 - 400 bp was excised. Gel slice was
puriﬁed with the Qiaquick gel extraction kit and 1 of 30 µL eluate was
used for a 50 µL ampliﬁcation reaction using Phusion HF Mastermix
(Finnzymes, Espoo, Finland) and 0.2 µM of each primer of pairs pairs
AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC
GCT CTT CCG ATC and CAA GCA GAA GAC GGC ATA CGA GAT CGG TCT
CGG CAT TCC TGC TGA ACC GCT CTT CCG ATC or ACA CTC TTT CCC TAC
ACGACG CTC TTC CGA TC and CTC GGC ATT CCT GCT GAA CCG CTC TTC
CGA TC. Cycling conditions were: 30 s, 98 °C, then 18 times 10 s, 98 °C;
30 s, 65 °C; 30 s, 72 °C; then 300 s, 72 °C. Puriﬁcation was performed
using the Qiaquick PCR puriﬁcation protocol. Libraries were analyzed
by Bioanalyzer analysis (Agilent, Santa Clara, USA), quantiﬁed by
Nanodrop 1000 UV measurement (Thermo Scientiﬁc, Waltham, USA)
and stored in water at -20 °C until use.
Sequence capture protocol
For four arrays, 6 µg adaptor-ligated gDNA library were dissolved
in febit Hybmix-4, heated to 95 °C for 5 min and placed on ice. Sample
mixture was placed into the sample loading station of the Geniom RT
Analyzer and automatically injected into the microﬂuidic channels of
the biochip. Sample was denatured within the chip at 80 °C for 10 min
and hybridized for 16 h at 42 °C with active movement of the sample.
After hybridization, each array was automatically washed with 6x
SSPE at room temperature and 0.5x SSPE at 45 °C. Each array was
subsequently washed with SSPE-based febit stringent wash buffers 1
and 2 at room temperature. All protocol steps were carried out in a
completely automated fashion by the Geniom RT Analyzer instrument
without manual interference. For elution of the enriched samples,
arrays were ﬁlled with 10 µL of 90% formamide in water each using an
elution holder and incubated at 70 °C for 30 min in an oven. Solution
was manually transfered into an Eppendorf tube and dried by vacuum
centrifugation in a Speed-Vac at 65 °C. After an ampliﬁcation step as
described under DNA sample preparation for 35 cycles, the sample
was treated like the original library and subjected to a second round of
enrichment under the same conditions as before.
Eluted samples were subjected to 10 cycles of PCR according to the
conditions described under DNA sample preparation and puriﬁed by
Qiagen MinElute PCR puriﬁcation (Qiagen, Hilden, Germany). Quan-
tiﬁcation of samples was done by the Quant-It Picogreen assay
(Invitrogen, Carlsbad, USA) using the Nanodrop 3300 instrument
(Thermo Scientiﬁc).
Data analysis
Paired-end Solexa reads (32.878.698 reads with 36 bp length for
replicate 1 or 20.700.622 reads with 50 bp in length for replicate
2) were ﬁrst ﬁltered by removing reads with ambiguous nucleotide
calls (3 or more N) and reads with 34 or more A (or T or C or G). This
resulted in 15.816.258 or 10.954.170 reads usable for mapping for the
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paired end sequences were aligned with target genes by using razerS,
which is part of SeqAn, an open source C++ library of efﬁcient
algorithms and data structures for the analysis of biological sequences
[29]. The parameters used were “-gn 1 -f -r -i 94 -rr 100 -m 10”which
allows up to 2 (36 bp reads) or 3 (50 bp reads) mismatches. The
output alignment ﬁles were matched for each pair of reads: the two
reads were mapped to opposite strands and in correct orientation and
the length between the two reads (inclusive) was within 100-500 bp.
The paired reads were further matched to extended regions covered
by probes (consensus) to get the reads on target. The fold coverage for
each base within the probe regions was calculated for unique reads.
For SNP calling, individual base fractions for each position having a
coverage of 5-fold or higher were calculated and positions were called
homozygous if one base accounted for at least 80% and all other bases
accounted for less than 10%. If two bases accounted for at least 20%
each, the position was called heterozygous. Each called base was
compared with UCSC genome hg18 (dbSNP130 masked version). If a
difference was found, this position was identiﬁed as SNP. SNPs existed
in dbSNP were separated from those new ones to calculate the
percentages of known vs. novel SNPs.
Results and Discussion
General Workﬂow for Exome Subset Capture and Sequencing
The overall HybSelect workﬂow makes use of two key hardware
components. The microﬂuidic Geniom Biochip containing eight
individual channels each harboring an array of 15624 freely
programmable DNA capture probes is used as sequence enrichment
matrix (Fig. 1A). This biochip is processed by the Geniom RT Analyzer
which allows for automated sample injection, hybridization with
temperature control and active mixing, washing protocols and
imaging (Fig. 1B). The HybSelect workﬂow consists of three basic
steps: preparation of a standard genomic DNA library for sequencing,
capturing of desired library fragments on the microﬂuidic arrays
including stringent washing to remove unwanted fragments andFig. 1. Hardware and workﬂow used in the HybSelect process. A: Top view of the microﬂui
oligonucleotide probes. B: Front view of the Geniom RT Analyzer, a fully integrated micro
mixing, temperature control, ﬂuidic control and ﬂuorescence detection. C: Workﬂow of the
library is constructed (2). Library is hybridized to a biochip containing capture probes for the
library fragments are eluted (5) and used for next generation sequencing (6).elution followed by next-generation-sequencing (Fig. 1C). Application
of the capture step after library preparation thereby allows facile
adaption to different NGS platforms, since all current platforms use
adaptor ligated libraries. Thus, no changes to suppliers linker
mediated PCR protocols are necessary to adjust library amounts
when needed.
We designed an exome subset capture array for enrichment of 115
genes identiﬁed in the Cancer Genome project of the Wellcome Trust
Sanger Institute as a set highly relevant to the onset of various cancer
types. Genes from thecancer gene census list excluding genes known for
translocation mutations were used. The ﬁnal array design contained
genes ranging in size from 2.8 to 73.0 Kb with 1819 exons having a
minimal, maximal and median size of 2 bp, 8686 bp and 134 bp,
respectively. The design covered a total genomic region of interest (ROI)
of 9.2 Mbwhich corresponds to a core exonic region of 0.48 Mb covered
by probes. ∼56.000 50-mer tiling probes targeting sense and antisense
strands in an alternating manner were synthesized with the Geniom
One instrument using ∼44% of the capacity of a biochip.
Two individual human DNA libraries of the well-characterized
Yoruban HapMap sample NA18507 [7,25,30] with length distributions
of 200-400 bp and adaptors for Illumina paired-end sequencing were
prepared, hybridized for 16 h on two different biochips, and the arrays
were washed to remove weakly bound library fragments. The
enriched, single stranded samples were eluted, ampliﬁed using
Illumina paired end primers and subjected to a second cycle of
hybridization and washing. After elution, samples were made double
stranded by a limited number of PCR cycles.
Sequencing on one lane of aﬂowcell of an IlluminaGA II instrument
for each sample using the paired-end mode yielded a total of 15.8 and
11.0 million individual paired end reads after ﬁltering for homopol-
ymeric or ambiguous reads and removal of reads not mapping
uniquely to the human genome.
Completeness and Uniformity of Target Coverage
Paired end reads were mapped against the genomic region
covered with capture probes and coverage was analyzed. For thedic Geniom Biochip with 8 individual channels each containing an array of 15624 DNA
array processing station allowing for automated sample injection, hybridization with
HybSelect process. Genomic DNA (1) is fragmented and a next generation sequencing
desired target sequences (3) and washed to remove unwanted fragments (4). Desired
Fig. 2.Uniformity of per base coverage visualized by a normalized coverage distribution
plot. Graph shows fraction of targeted exons exhibiting a target coverage equal or
higher than the normalized target coverage shown on the x-axis. Normalized target
coverage was calculated by dividing individual median target coverages of exons by the
median target coverage for all exons. For 0.5- and 0.2-fold of normalized target
coverage, exon fractions are indicated as dotted lines.
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tages of the target covered at least once, were N96% for both samples
(Table 1). For percentages of exon- and gene-wise median coverages,
numbers increased to N97% and 100%, respectively. This completeness
is in line with previous studies and shows only negligible dropout of
target sequence (For a detailed, gene-wise analysis of on-target reads,
average target coverages, and percentages of target covered ≥1-, 5-
and 10-fold, see Supplementary Table 1).
Beside completeness of coverage, the uniformity of coverage depth
is an important parameter of a sequence capture method, since even
coverage avoids redundant reads in over-captured regions.
Analysis for all 115 genes revealed that 96% of all genes were in a
range of coverage depth of b1 log. This indicates a low dependence of
capture efﬁciency on individual genes and suggests wide applicability
of the method to various sequence contexts. A more detailed analysis
of coverage uniformity is shown in Fig. 2. The individual median target
coverages of all 1819 exons for both replicates were normalized by
dividing them by the median target coverage of all exons. By plotting
the fraction of total exons exhibiting a speciﬁc normalized target
coverage, it is possible to analyze and compare coverage uniformity of
experiments independently of e.g. platform-dependent effects or
overall sequence yield [15,22]. Of all exons, 46.9% and 48.8% exhibited
the median target coverage or more, respectively. 69.7% and 68.1%
had a normalized target coverage of 0.5 and 84.3% and 85.0% of 0.2.
This data indicates similar or better uniformity compared to recently
reported studies for solution-phase exonic capture experiments
combined with Illumina NGS technology [15–17].
For further improvements, we sought to elucidate the origin of
target coverage variability for individual exons. Fig. 3 shows the actual
median target coverages of replicate 1 either for all exons (A) or in
dependence of GC content of exons (B). A clear trend is visible that
comparably low target coverage is obtained for GC contents outside of
an optimum range with a lower limit of ∼40% and a higher limit of
∼60%. This trend is more dominant for exons with low GC contents
compared to high GC contents. Overall, 58.5% of all exons fell into the
optimum range of 40-60%. For these exons, an excellent completeness
of 99.2% was obtained with 98.5% of exons having a target coverage of
5-fold or higher. These data suggest that applying more stringent GC-
content criteria during probe design might substantially improve
performance of the approach.
Another aspect for further improvement is the dependence of
target coverage and exon size. Since sizes of targeted exons span a
large range between 2 – 8686 bp, we were interested in dependence
of exon-wise median target coverage and exon size. A histogram
analysis revealed low variation of target coverage between exons of
middle and larger sizes (Supplementary Fig. 1). However, it alsoTable 1
Statistics of mapping of sequencing reads obtained from Illumina paired end sequencing of t
ROI (region of interest), the target (exonic region covered by capture probes), the numbe
average target coverages (fold) and percentages of target covered at a depth of at least 1-fo
wise.
General Metrics: ROI Target
Replicate 1 9345045 482093
Replicate 2 9345045 482093
Percent of Bases covered: @ ≥1-fold @ ≥5-fold
Replicate 1 97.2 93
Replicate 2 96.5 88.6
Percent of Exons covered: @ ≥1-fold @ ≥5-fold
Replicate 1 98.5 95.8
Replicate 2 97.8 93.4
Percent of Genes covered: @ ≥1-fold @ ≥5-fold
Replicate 1 100 100
Replicate 2 100 100pointed at a possibility for a facile further improvement of the
method. Very small exons (1-30 bp) exhibited relatively low median
target coverage of only 9.5-fold whereas exons 31-60 bp in size were
covered at a median of 73-fold with a trend for even higher target
coverages for larger exons. Hence, overall performance could also be
increased by using denser tiling schemes for extended regions around
very small exons.
Detection of Single Nucleotide Polymorphisms (SNP)
Since resequencing for variant discovery is currently the most
important application of NGS platforms, a crucial parameter of any
sequence enrichment method for NGS is its potential to detect and
correctly call novel SNPs. For such an analysis, we included all exon
bases of Yoruban HapMap sample NA18507 with coverages of 5-
fold or higher which has been used as quality criterion for SNP
calling previously [16]. This corresponds to a SNP calling sensitivity
(percent of target sufﬁciently covered for SNP detection) of 88.6 –
93% (Table 1). In these regions, 4998 and 4702 coding SNPs
(cSNPs) were detected in the two samples, respectively. A
comparison with dbSNP revealed that 89.2% and 91.0% of these
SNPs were matching previous database entries. This compares to
74% matches recently obtained for a genome-wide comparison ofwo replicate samples enriched for exons of 115 cancer genes. Shown are the sizes of the
r of on-target reads obtained by the two individual sequencing runs of one lane each,
ld, 5-fold, 10-fold and 20-fold. Percentages are shown base-wise, exon-wise and gene-
On Target Reads Average Target Coverage
2663643 183.82
817614 74.05
@ ≥10-fold @ ≥20-fold
89.4 83.3
80.5 68.9
@ ≥10-fold @ ≥20-fold
93.2 86.4
84.3 71.2
@ ≥10-fold @ ≥20-fold
100 100
100 93.9
Fig. 3. Exon-wise analysis of median target coverages obtained frommapping of paired end reads of an Illumina GAII sequencing run with sample replicate 1 enriched for 115 cancer
related genes. A: Shown is the median fold target coverage for the 1819 individual exons. X-axis shows the individual exon number, y-axis shows the median target coverage for
individual exons. B: Median per base coverage for 1819 exons in dependence on exons GC content. X-axis shows the individual median target coverage for exons, y-axis shows the
GC content of individual exons in percent.
245D. Summerer et al. / Genomics 95 (2010) 241–246Illumina sequencing data of the identical HapMap sample [7].
However, in a recent whole exome sequencing project of this
sample using Illumina technology, 89.1% concordance was obtained
for cSNPs only, which closely mirrors the concordance obtained for
our solely exonic target [25].
This indicates a low potential of the approach for false positive calls
that could originate from e.g. suboptimal conditions of enrichment,
sequencing or mapping methods and would cause an excess of newly
identiﬁed SNPs vs. previously known database entries.
We next analyzed the percental nucleotide representations of all
HapMap reference SNP positions contained in the targeted exons. 836
SNPs with reference data were present in the captured regions that
were used for further analysis. Of 836 SNPs, 790 (94.5%) and 754
(90.2%) SNPs were thereby covered 5-fold or higher for the two
replicates. Nucleotide analysis and comparison to HapMap reference
data (HM-All, data from all HapMap project phases) revealed an
overall concordance of 98.2% and 99.1% for all SNPs, similar to
speciﬁcities reported previously for array based sequence capture
[14,22,27] and other enrichment methods [15–17]. Generally,
speciﬁcity could be further enhanced by increasing the minimum
depths of coverage used for ﬁltering of callable positions, however, for
the cost of decreasing sensitivities [7,8].
To further understand the origin of SNP calling discrepancies
between targeted Illumina sequencing and HapMap genotyping
results, we made a follow-up analysis for all non-concordant SNP
positions. Different types of discrepancies thereby may hint at
different error sources. For example, heterozygous sequencing calls
for homozygous HapMap genotypes may hint at accidental base
substitutions generated by PCR during library preparation or the
HybSelect process when present in one replicate. Presence in both
replicates may rather hint at a systematic error e.g. in sequencing,
read mapping or HapMap genotyping, since random PCR artifacts in
both samples seem unlikely. However, a systematic error that could
be associated with a hybridization-based sequence capture method
may be loss of heterozygousity due to preferential binding of capture
probes to the complementary allele. In our study, there were 21 non-
concordant calls found at 14 different positions within the total 1544
calls for SNPs with coverage at 5-fold or higher for both replicates (see
Supplementary Table 2). Of these, only 6 (5 positions) were missed
heterozygote alleles of which only two occurred in both replicates. In
contrast, the majority of discrepancies (12 at 6 positions) were called
in both replicates of the sample with almost identical base fractions,
suggesting systematic errors that are independent of the sequencecapture process. Three positions had relatively low coverage of ≤8-
fold and one position had coverage of ≥5-fold in only one of the
replicates.
These data suggest that the majority of non-concordant calls are
due to systematic errors in process steps aside from the actual
HybSelect procedure and that the actual calling speciﬁcity is
substantially higher than stated above. Additionally, speciﬁcity
might increase even further with higher coverage depth of SNPs
that were covered poorly.
Conclusion
Taken together, we present a highly scalable method to enrich
focused, biologically relevant exome subsets with increased sample
numbers. The method provides excellent completeness of coverage
with similar or better coverage uniformity than previously reported
for exonic targets. This is reﬂected by high sensitivity and speciﬁcity of
SNP calling. Our data further suggest that this performance could be
even further increased by relatively simple alterations of protocol
parameters, i.e. probe design algorithms in terms of GC content and
tiling density for very small exons. Microﬂuidic array architecture
with associated short hybridization times and a high level of
automation throughout the procedure thereby enables fast processing
and easy handling with potential beneﬁts for cost, reproducibility and
contamination.
The method efﬁciently amends technologies involved in large-
scale discovery studies such as whole genome or whole exome
sequencing. For efﬁcient follow-up projects involving massive sample
numbers, scalability of enrichment methods becomes crucial to
reduce needed capacities of enrichment and sequencing instrumen-
tation. The architecture of the presented biochip features eight
individual array channels with free scalability between 0.125 and
1 Mb and/or one and eight samples. Depending on target size, a
throughput of eight samples per two days is the current throughput
without barcoding strategies. However, since coverage of most target
bases obtained is signiﬁcantly higher than the threshold of ≥5-fold
used for SNP calling, it is reasonable to assume that a severalfold
increase in throughput could be achieved by barcoding with limited
loss in sensitivity.We envision that current efforts for improvement of
probe design along the parameters identiﬁed in this study as well as
further increase in read lengths and numbers of NGS instruments will
again strongly increase the potential for massive multiplexing with
high numbers of barcoded samples.
246 D. Summerer et al. / Genomics 95 (2010) 241–246Beside the cancer-related biochip presented here, we currently
design further pre-evaluated sub-exome biochips for various ﬁelds
such as neurodegenerative or cardiovascular disease, drug response or
human aging.
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